[go: up one dir, main page]

PL390420A1 - Spirocykliczne pochodne cykloheksanu, sposoby ich wytwarzania, ich zastosowania oraz środek leczniczy zawierający te związki - Google Patents

Spirocykliczne pochodne cykloheksanu, sposoby ich wytwarzania, ich zastosowania oraz środek leczniczy zawierający te związki

Info

Publication number
PL390420A1
PL390420A1 PL390420A PL39042003A PL390420A1 PL 390420 A1 PL390420 A1 PL 390420A1 PL 390420 A PL390420 A PL 390420A PL 39042003 A PL39042003 A PL 39042003A PL 390420 A1 PL390420 A1 PL 390420A1
Authority
PL
Poland
Prior art keywords
cyclohexane derivatives
spirocyclic cyclohexane
spirocyclic
derivatives
cyclohexane
Prior art date
Application number
PL390420A
Other languages
English (en)
Other versions
PL217804B1 (pl
Inventor
Claudia Hinze
Otto Aulenbacher
Stefan Oberborsch
Werner Günter Englberger
Babette-Yvonne Kögel
Klaus Linz
Hans Schick
Helmut Sonnenschein
Brigitta Henkel
Sally Rose
Mike Lipkin
Elmar Josef Friderichs
Bernd Sundermann
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL390420(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of PL390420A1 publication Critical patent/PL390420A1/pl
Publication of PL217804B1 publication Critical patent/PL217804B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/06—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL390420A 2002-11-11 2003-11-05 Spirocykliczne pochodne cykloheksanu, sposoby ich wytwarzania, ich zastosowania oraz środek leczniczy zawierający te związki PL217804B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2002152667 DE10252667A1 (de) 2002-11-11 2002-11-11 Spirocyclische Cyclohexan-Derivate

Publications (2)

Publication Number Publication Date
PL390420A1 true PL390420A1 (pl) 2010-04-26
PL217804B1 PL217804B1 (pl) 2014-08-29

Family

ID=32185555

Family Applications (2)

Application Number Title Priority Date Filing Date
PL390420A PL217804B1 (pl) 2002-11-11 2003-11-05 Spirocykliczne pochodne cykloheksanu, sposoby ich wytwarzania, ich zastosowania oraz środek leczniczy zawierający te związki
PL376793A PL215227B1 (pl) 2002-11-11 2003-11-05 Spirocykliczne pochodne cykloheksanu, sposoby ich wytwarzania, ich zastosowania oraz srodek leczniczy zawierajacy te zwiazki

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL376793A PL215227B1 (pl) 2002-11-11 2003-11-05 Spirocykliczne pochodne cykloheksanu, sposoby ich wytwarzania, ich zastosowania oraz srodek leczniczy zawierajacy te zwiazki

Country Status (28)

Country Link
US (6) US7547707B2 (pl)
EP (4) EP1560835B1 (pl)
JP (4) JP4728645B2 (pl)
KR (2) KR101075810B1 (pl)
CN (2) CN100577664C (pl)
AR (2) AR041932A1 (pl)
AT (1) ATE441650T1 (pl)
AU (2) AU2003296563B2 (pl)
BR (2) BRPI0318811B8 (pl)
CA (1) CA2505555C (pl)
CO (1) CO5580765A2 (pl)
CY (2) CY1110558T1 (pl)
DE (2) DE10252667A1 (pl)
DK (2) DK2062898T3 (pl)
EC (1) ECSP055786A (pl)
ES (4) ES2587185T3 (pl)
HK (3) HK1130491A1 (pl)
IL (2) IL168473A (pl)
MX (1) MXPA05004959A (pl)
NO (2) NO331818B1 (pl)
NZ (1) NZ540575A (pl)
PE (1) PE20040830A1 (pl)
PL (2) PL217804B1 (pl)
PT (2) PT1560835E (pl)
RU (1) RU2354656C2 (pl)
SI (2) SI2062898T1 (pl)
WO (1) WO2004043967A1 (pl)
ZA (1) ZA200504725B (pl)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DK1658054T3 (da) * 2003-08-06 2007-10-01 Gruenenthal Gmbh Indgivelsesform, som er sikret mod misbrug
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005016460A1 (de) 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
US20070149557A1 (en) * 2005-11-21 2007-06-28 Amgen Inc. CXCR3 antagonists
DE102006019597A1 (de) * 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102006033114A1 (de) * 2006-07-18 2008-01-24 Grünenthal GmbH Spirocyclische Azaindol-Derivate
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102007009235A1 (de) * 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007009319A1 (de) * 2007-02-22 2008-08-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
CA2719736C (en) * 2008-03-27 2016-02-09 Gruenenthal Gmbh Spiro(5.5)undecane derivatives
NZ600210A (en) 2008-03-27 2013-08-30 Gruenenthal Chemie Substituted 4-aminocyclohexane derivatives
WO2009118163A1 (de) 2008-03-27 2009-10-01 Grünenthal GmbH (hetero-)aryl-cyclohexan-derivate
SI2260042T1 (sl) * 2008-03-27 2011-11-30 Gruenenthal Gmbh Substituirani spirociklični cikloheksanski derivati
WO2009118174A1 (de) 2008-03-27 2009-10-01 Grünenthal GmbH Substituierte cyclohexyldiamine
JP5599774B2 (ja) * 2008-03-27 2014-10-01 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ヒドロキシメチルシクロヘキシルアミン類
CN102123701B (zh) 2008-05-09 2013-03-27 格吕伦塔尔有限公司 使用喷雾冻凝步骤制备中间粉末制剂以及最终固体剂型的方法
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
HUE042987T2 (hu) * 2009-07-22 2019-07-29 Gruenenthal Gmbh Visszaéléssel szemben ellenálló adagolási forma oxidációra érzékeny opioidok számára
US8710245B2 (en) * 2009-12-04 2014-04-29 Psychogenics Inc. Multicyclic compounds and methods of use thereof
TWI582092B (zh) * 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
PL2600850T3 (pl) 2010-08-04 2019-06-28 Grünenthal GmbH Farmaceutyczna postać dawkowania zawierająca 6'-fluoro-(n-metylo- lub n,n-dimetylo-)-4-fenylo-4',9'-dihydro-3'h-spiro[cykloheksano-1,1'-pirano[3,4,b]indolo]-4-aminę do leczenia bólu nocyceptywnego
BR112013002714A2 (pt) 2010-08-04 2017-05-30 Gruenenthal Gmbh forma de dosagem farmacêutica compreendendo 6-fluor-(n-metil- ou n,n-dimetil)-4-fenil-4,9-di-hidro-3h-espiro[ciclo-hexano-1,1-pirano[3,4,b]indol]-4-amina
PL2600846T3 (pl) * 2010-08-04 2016-05-31 Gruenenthal Gmbh Farmaceutyczna postać dawki zawierająca 6'-fluoro-(n-metylo- albo N,N-dimetylo-)-4-fenylo-4',9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4,b]indol]-4-aminę
DK2600838T3 (en) * 2010-08-04 2015-10-05 Gruenenthal Gmbh PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL- OR N, N-DIMETHYL-) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3 , 4, b] indole] -4-amine.
ES2534847T3 (es) 2010-09-02 2015-04-29 Grünenthal GmbH Forma de dosificación inviolable que comprende un polímero aniónico
EP2611425B1 (en) 2010-09-02 2014-07-02 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
PL2649044T3 (pl) 2010-12-08 2018-02-28 Grünenthal GmbH Sposób syntezy podstawionych pochodnych aminocykloheksanonu
US8614245B2 (en) 2011-07-08 2013-12-24 Gruenenthal Gmbh Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
US8618156B2 (en) * 2011-07-08 2013-12-31 Gruenenthal Gmbh Crystalline (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
US8895604B2 (en) * 2011-12-12 2014-11-25 Gruenenthal Gmbh Solid forms of (1r,4r)-6′-fluoro-N,N-dimethy1-4-phenyl-4′,9′-dihydro-3′ H-spiro-[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine hydrochloride
MX359343B (es) * 2011-12-12 2018-09-26 Gruenenthal Gmbh Proceso para la preparación de (1r,4r)-6´-fluoro-(n,n-dimetil- y n-metil)-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexano-1,1´-pirano -[3,4,b]indol]-4-amina.
RS54960B1 (sr) * 2011-12-12 2016-11-30 Gruenenthal Gmbh Čvrsti oblici (1r,4r)-6'-fluoro-(n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-spiro-[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amina i sumporne kiseline
WO2013113690A1 (en) 2012-01-31 2013-08-08 Grünenthal GmbH Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
CN104168897B (zh) * 2012-02-03 2016-09-28 格吕伦塔尔有限公司 用于治疗纤维肌痛和慢性疲劳综合征的(1r,4r)-6’-氟-(N-甲基-或N,N-二甲基-)-4-苯基-4’,9’-二氢-3’H-螺-[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺
EP2819657A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
AU2013225106B2 (en) 2012-02-28 2017-11-02 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
HUE036985T2 (hu) 2012-03-23 2018-08-28 Codexis Inc Biokatalizátor és eljárások triptamin és triptamin-analógok származékainak szintetizálására
CA2868142A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
RS56685B1 (sr) 2012-05-11 2018-03-30 Gruenenthal Gmbh Termoformirani farmaceutski dozni oblik otporan na zloupotrebu koji sadrži cink
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9308196B2 (en) 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
HUE037195T2 (hu) 2013-03-15 2018-08-28 Gruenenthal Gmbh Kristályos cisz-(E)-4-(3-fluorfenil)-2',3',4',9'-tetrahidro-N,N-dimetil-2'-(1-oxo-3-fenil-2-propenil)- spiro[ciklohexán-1,1'[1H]-pirido[3,4-B]indol]-4-amin
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
US20150164807A1 (en) 2013-12-16 2015-06-18 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion
EP3110797B1 (en) 2014-02-27 2018-08-29 Grünenthal GmbH Process for the preparation of 5-fluorotryptophol
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
RS57732B1 (sr) 2014-07-15 2018-12-31 Gruenenthal Gmbh Supstituisani derivati azaspiro(4.5)dekana
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
AU2016208779B2 (en) 2015-01-23 2020-11-12 Grunenthal Gmbh Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
EP3253374B1 (en) 2015-02-02 2018-11-28 ratiopharm GmbH Composition comprising cebranopadol in a dissolved form
JP2018503693A (ja) 2015-02-03 2018-02-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ポリエチレングリコールグラフトコポリマーを含む改変防止剤形
US20160310429A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CN108271369A (zh) 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
BR112018014302B1 (pt) * 2016-01-13 2023-10-17 Grünenthal GmbH Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
LT3402782T (lt) * 2016-01-13 2020-10-12 Grünenthal GmbH 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai
CA3011180A1 (en) * 2016-01-13 2017-07-20 Grunenthal Gmbh 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
SI3402784T1 (sl) * 2016-01-13 2020-07-31 Gruenenthal Gmbh Derivati 3-((hetero)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana
PT3402781T (pt) * 2016-01-13 2020-07-07 Gruenenthal Gmbh Derivados de 3-((hetero-)aril)-8-amino-2-oxo-1,3-diazaespiro[ 4.5]decano
WO2017148595A1 (en) 2016-02-29 2017-09-08 Grünenthal GmbH Titration of cebranopadol
WO2018007507A1 (en) 2016-07-06 2018-01-11 Grünenthal GmbH Reinforced pharmaceutical dosage form
TW201908295A (zh) 2017-07-12 2019-03-01 德商歌林達有限公司 １，３－二氮雜－螺－［３．４］－辛烷衍生物
EP3613747A1 (en) 2018-08-24 2020-02-26 Grünenthal GmbH Crystalline forms of trans-6'-fluoro-n-methyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
KR20220131520A (ko) 2019-12-26 2022-09-28 길가메쉬 파마슈티컬스, 인코포레이티드 아릴시클로헥실아민 유도체 및 정신장애 치료에서의 이의 용도
NZ790704A (en) 2020-02-18 2024-12-20 Gilgamesh Pharmaceuticals Inc Specific tryptamines for use in the treatment of mood disorders
CN112279813B (zh) * 2020-10-29 2023-02-28 上海中医药大学 1-环己基吡唑啉酮类羧酸酯酶1抑制剂、其制备及应用
WO2024129782A1 (en) 2022-12-12 2024-06-20 Park Therapeutics, Inc. Regimens and compositions useful for alleviating pain
WO2024173714A1 (en) 2023-02-15 2024-08-22 Park Therapeutics, Inc. Regimens and compositions useful for alleviating pain
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12180158B1 (en) 2023-08-03 2024-12-31 Gilgamesh Pharmaceuticals, Inc. Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055203A (en) 1964-09-16 1967-01-18 Ici Ltd -ß-carboline derivatives, a process for their manufacture, and compositions containing them
US3843681A (en) * 1971-06-01 1974-10-22 American Home Prod 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives
US4021451A (en) * 1972-05-16 1977-05-03 American Home Products Corporation Process for preparing polycyclic heterocycles having a pyran ring
JPS5638594A (en) * 1979-09-05 1981-04-13 Toshiba Corp Multistage capability controlling method
US4291039A (en) 1980-08-08 1981-09-22 Miles Laboratories, Inc. Tetrahydro β-carbolines having anti-hypertensive activity
DE3309596A1 (de) 1982-08-05 1984-04-05 Basf Ag, 6700 Ludwigshafen 2-substituierte 1-(3'-aminoalkyl)-1,2,3,4-tetrahydro-ss-carboline, ihre herstellung und verwendung als arzneimittel
US5328905A (en) 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
FR2663935A1 (fr) * 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
EP0620222A3 (en) 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
US5631265A (en) 1994-03-11 1997-05-20 Eli Lilly And Company 8-substituted tetrahydro-beta-carbolines
US5861408A (en) 1995-05-19 1999-01-19 Eli Lilly And Company Tetrahydro-Beta-Carbolines
DE69729211T2 (de) * 1996-03-25 2005-05-04 Eli Lilly And Co., Indianapolis Tetrahydro-beta carbolinverbindungen
US20040038970A1 (en) 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
JP2002517500A (ja) * 1998-06-12 2002-06-18 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス β−カルボリン化合物
CA2356269A1 (en) * 1998-12-24 2000-07-06 Yoshihisa Akiyama Pain control agent
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US20060235012A1 (en) * 2003-06-16 2006-10-19 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
CA2540343A1 (en) * 2003-10-02 2005-04-14 Cephalon, Inc. Indole derivatives
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
DE102005016460A1 (de) * 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
EP1747779A1 (en) 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands
US20070149557A1 (en) 2005-11-21 2007-06-28 Amgen Inc. CXCR3 antagonists
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz

Also Published As

Publication number Publication date
CY1110558T1 (el) 2015-04-29
CN100577664C (zh) 2010-01-06
EP1560835B1 (de) 2009-09-02
CN1735619A (zh) 2006-02-15
SI1560835T1 (sl) 2010-01-29
US20060004034A1 (en) 2006-01-05
NO20093060L (no) 2005-06-07
JP2010006815A (ja) 2010-01-14
PL215227B1 (pl) 2013-11-29
EP2062898A2 (de) 2009-05-27
PL217804B1 (pl) 2014-08-29
CN101693714B (zh) 2013-05-29
AU2010200219B2 (en) 2012-04-12
IL168473A (en) 2012-10-31
CY1114616T1 (el) 2016-10-05
EP2233487A1 (de) 2010-09-29
US20090163716A1 (en) 2009-06-25
EP2116544A3 (de) 2010-09-22
HK1146044A1 (zh) 2011-05-13
CA2505555A1 (en) 2004-05-27
ES2587013T3 (es) 2016-10-20
AU2003296563A1 (en) 2004-06-03
BRPI0318811B1 (pt) 2020-11-03
AU2003296563B2 (en) 2010-03-11
EP2062898B1 (de) 2013-10-02
PL376793A1 (pl) 2006-01-09
JP4728645B2 (ja) 2011-07-20
HK1080478A1 (en) 2006-04-28
JP2006508114A (ja) 2006-03-09
PE20040830A1 (es) 2004-11-17
US9862719B2 (en) 2018-01-09
KR101075810B1 (ko) 2011-10-25
ES2587185T3 (es) 2016-10-21
KR20050074579A (ko) 2005-07-18
EP1560835A1 (de) 2005-08-10
DK1560835T3 (da) 2010-01-04
US9120797B2 (en) 2015-09-01
HK1130491A1 (en) 2009-12-31
DE50311874D1 (en) 2009-10-15
NO20052761L (no) 2005-06-07
ECSP055786A (es) 2005-08-11
DK2062898T3 (da) 2013-10-28
NO331818B1 (no) 2012-04-10
BRPI0315296B8 (pt) 2021-05-25
AR041932A1 (es) 2005-06-01
JP2011016829A (ja) 2011-01-27
EP2233487B1 (de) 2016-05-18
JP5539821B2 (ja) 2014-07-02
US8053576B2 (en) 2011-11-08
RU2005118403A (ru) 2006-04-27
PT2062898E (pt) 2013-10-22
EP2116544B1 (de) 2016-05-18
ES2333956T3 (es) 2010-03-03
KR20090129521A (ko) 2009-12-16
RU2354656C2 (ru) 2009-05-10
KR101075817B1 (ko) 2011-10-25
WO2004043967A1 (de) 2004-05-27
JP2010270155A (ja) 2010-12-02
CA2505555C (en) 2011-01-04
ES2438269T3 (es) 2014-01-16
BRPI0318811B8 (pt) 2021-05-25
BRPI0315296B1 (pt) 2018-10-09
NO20052761D0 (no) 2005-06-07
SI2062898T1 (sl) 2013-11-29
US7547707B2 (en) 2009-06-16
US7799931B2 (en) 2010-09-21
US20090156626A1 (en) 2009-06-18
AU2010200219A1 (en) 2010-02-11
EP2062898A3 (de) 2010-09-22
NO331776B1 (no) 2012-03-26
US20110319440A1 (en) 2011-12-29
ZA200504725B (en) 2006-08-30
ATE441650T1 (de) 2009-09-15
MXPA05004959A (es) 2005-08-02
DE10252667A1 (de) 2004-05-27
IL203141A (en) 2012-04-30
AR074529A2 (es) 2011-01-26
JP5442565B2 (ja) 2014-03-12
PT1560835E (pt) 2009-12-10
EP2116544A2 (de) 2009-11-11
US20100240897A1 (en) 2010-09-23
CN101693714A (zh) 2010-04-14
US7951948B2 (en) 2011-05-31
US20150322080A1 (en) 2015-11-12
BR0315296A (pt) 2005-08-30
CO5580765A2 (es) 2005-11-30
NZ540575A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
HK1080478A1 (en) Spirocyclic cyclohexane derivatives
PT1697379E (pt) Derivados de ciclo-hexano espirocíclicos
EG23484A (en) Cis-alkoxy substituted spirocyclic 1H-pyrolidine2-4 dione derivatives
IL176457A0 (en) Spirocyclic cyclohexane derivatives with affinity for the orl1-receptor
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
IL169905A0 (en) Novel 2-pyridinecarboxamide derivatives
HK1077068A1 (en) Azolidinone-vinyl fused-benzene derivatives
IL166121A0 (en) Indole-3-sulphur derivatives
EP1522540A4 (en) AZAARENE DERIVATIVES
PL376475A1 (pl) Pochodne N-podstawionej 2-oksodihydropirydyny
IL166426A0 (en) N-biarylmethyl aminocycloalkanecarboxamide derivatives
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
EP1531854A4 (en) O-DERIVATED NOCATHIACIN DERIVATIVES
GB0213488D0 (en) 2-Naphthamide derivatives
AU2003243397A8 (en) Homo-camptothecin derivatives
IL162104A0 (en) Substituted cyclohexane derivatives
SI1654253T1 (sl) Substituirani 3-pirolidin-indolni derivati
GB0210512D0 (en) Tetrahydro-napthalene derivatives
GB0219894D0 (en) Dihydropyridinone derivatives
AU2003285777A8 (en) 3-substituted-4-pyrimidone derivatives